Chemotherapy for elderly patients with advanced colorectal carcinoma

Expert Review of Anticancer Therapy

Volumn 6, Issue 5, 2006, Pages 795-800

  Gallego, Rosa ^a   Sanchez, Nuria ^b   Maurel, Joan ^c  

^a Medical Service   (Spain)

^b Oncology Unit   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Advanced colorectal cancer; Fit patients; Frailty; Quality of life

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; RALTITREXED; UFT;

ADVANCED CANCER; AGED; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLORECTAL CARCINOMA; COLORECTAL SURGERY; COMORBIDITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CRYOTHERAPY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; ECHOGRAPHY; FRAIL ELDERLY; GERIATRIC ASSESSMENT; GERIATRIC DISORDER; HAND FOOT SYNDROME; HUMAN; MONOTHERAPY; MUCOSA INFLAMMATION; NEPHROTOXICITY; PATIENT COMPLIANCE; PROGNOSIS; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; RISK BENEFIT ANALYSIS; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SURVIVAL TIME; AGE; CARCINOMA; COLORECTAL TUMOR; DECISION MAKING; PATHOLOGY;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA; COLORECTAL NEOPLASMS; DECISION MAKING; FRAIL ELDERLY; HUMANS; NEOPLASM STAGING; QUALITY OF LIFE;

EID: 33745164332     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.5.795     Document Type: Review

References (73)

1. Benson AB, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K. Oncologist reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J. Clin. Oncol. 9, 2067-2075 (1991).
2. Hutchins LF, Unger JM, Crowley JJ et al. Under-representation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 241, 2061-2066 (1999).
3. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Br. Med. J. 32, 351-355 (2000).
4. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041-1047 (2000).
5. De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18, 2938-2947 (2000).
6. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22, 229-237 (2004).
7. Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of he Gruppo Oncologico Dell'Italia Meridionale. J. Clin. Oncol. 23, 4866-4875 (2005).
8. Balducci L. Evidence-based management of cancer in the elderly. Cancer Control 7, 368-376 (2000).
9. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 5, 224-237 (2000).
10. Balducci L, Ershler WB. Cancer and ageing: a nexus at several levels. Nat. Rev. Cancer 5, 655-662 (2005).
11. Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat. Rev. 31, 380-402 (2005).
12. Stuck AE, Siu AL, Wieland GD et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 342, 1032-1036 (1993).
13. Extermann M, Meyer J, McGinnis M et al. A comprehensive geriatric intervention detect multiple problems in older breast cancer patients. Crit. Rev. Oncol. Hematol. 49, 69-75 (2004).
14. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. 56, 146-156 (2001).
15. Lachs MS, Feinstein AR, Coonley LM et al. A simple procedure for general screening for functional disanility in elderly patients. Ann. Intern. 112, 699-706 (1990).
16. Moore AA, Siu AL. Screening for common problems in ambulatory elderly: clinical confirmation of a screening instrument. Am. J. Med. 100, 438-443 (1996).
17. Moore AA, Siu AL, Partridge BA et al. A randomized trial of office-based screening for common problems in older persons. Am. J. Med. 102, 371-378 (1997).
18. Povoski SP, Fong Y, Sgouros SC et al. Role of chest CT in patients with negative chest x-rays referred for hepatic colorectal metastases. Ann. Surg. Oncol. 5, 9-15 (1998).
19. Fong Y, Saldinger PF, Akhurst T et al. Utility of F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am. J. Surg. 178, 282-287 (1999).
20. Strasberg SM, Dehdashti F, Siegel BA et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann. Surg. 233, 293-299 (2001).
21. Arhurst T, Kates TJ, Mazumdar M et al. Recent chemotherapy reduces the sensitivity of fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J. Clin. Oncol. 23, 8713-8716 (2005).
22. Van Der Molen B. Relating information needs to the cancer experience. Eur. J. Cancer 8, 238-244 (1999).
23. Ainslie N, Beisecker AE. Changes in decisions by elderly persons based on treatment description. Arch. Intern. Med. 154, 2225-2233 (1994).
24. Ajaj A, Singh MP, Abdulla AJ. Should elderly patients be told they have cancer? Br. Med. J. 323, 1160 (2001).
25. Kahana E, Kahana B. Patient pro-activity enhancing doctor-patient-family communication in cancer prevention and care among the aged. Patient Educ. Couns. 50, 67-73 (2003).
26. Greene MG, Adelman RD, Majerovitz SD. Physician and older patient support in the medical encounter. Health Commun. 8, 263-279 (1996).
27. Greene M, Majerovitz D, Adelman R, Rizzo C. The effects of the presence of a third person on the physician-older patient medical interview. J. Am. Geriatr. Soc. 42, 413-419 (1994).
28. Greene MG, Hoffman S, Charon R, Adelman R. Psychosocial concerns in the medical encounter: a comparison of the interactions of doctors with their old and young patients. Gerontologist 27, 164-168 (1987).
29. Kutner JS, Vu KO, Prindiville SA, Byers TE. Patient age and cancer treatment decisions. Patient and physician views. Cancer Pract. 8, 114-119 (2000).
30. Velikova G, Stark D, Selby P. Quality of life instruments in oncology. Eur. J. Cancer 35, 1571-1580 (1999).
31. Bennabum D, Forman W, Vellas B, Albarete J. Life expectancy, comorbidity, and quality of life. Clin. Geriatr. Med. 13, 33-53 (1997).
32. Dancey J, Zee B, Osoba D et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual. Life Res. 6, 151-158 (1997).
33. Detmar SB, Aaronson NK. Quality of life assessment in daily clinical oncology. Eur. J. Cancer 34, 1181-1186 (1998).
34. Glimelius B, Hoffman K, Olafsdottir M, Palman L, Sjoeden P, Wennberg A. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens. Eur. J. Cancer Clin. Oncol. 25, 829-835 (1989).
35. Sprangers MA, te Velde A, Aaronson NK et al. The construction and testing of the EORTC colorrectal cancer-specific quality of life questionnaire module (QLQ-CR38). Eur. J. Cancer 35, 238-247 (1999).
36. Ward WL, Hahn EA, Mo F et al. Reliability and validity of the functional assessment of cancer therapy-colorrectal (FACT-C) QOL instrument. Qual. Life Res. 8, 181-195 (1999).
37. Ware JE Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36). Conceptual framework and item selection. Med. Care 30, 473-483 (1992).
38. Ware Jr J, Kosinsky M, Keller SD. A 12-item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med. Care 34, 220-223 (1996).
39. Thomé B, Dykes AK, Hallberg IR. Quality of life in old people with and without cancer. Qual. Life Res. 13, 1067-1080 (2004).
40. Thomé B, Hallberg IR. Quality of life in older people with cancer-a gender perspective. Eur. J. Cancer Care 13, 454-463 (2004).
41. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann. Surg. 230, 663-669 (1999).
42. Nagano Y, Nojiri K, Matsuo K et al. The impact of advanced age on hepatic resection of colorectal liver metastases. J. Am. Coll. Surg. 201, 511-516 (2005).
43. Yan TD, Padang R, Morris DL. Long-term results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: long term survival can be achieved with multiple liver metastases. J. Am. Coll. Surg. 202, 100-111 (2006).
44. Rhim H, Dodd GD. Radiofrequency thermal ablation of liver tumors. J. Clin. Ultrasound 27, 221-229 (1999).
45. Berber E, Siperstein AE. Predictors of survival after radiofrequency termal ablation of colorectal cancer metastases to the liver. J. Clin. Oncol. 23, 1358-1364 (2005).
46. Curley SA, Izzo F, Delrio P et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann. Surg. 230, 1-8 (1999).
47. Wood TF, Rose DM, Chung M et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann. Surg. Oncol. 7, 593-600 (2000).
48. Solbiati L, Livraghi T, Goldberg SN et al. Percutaneous radiofrequency ablation of hepatic metastases from colorectal cancer. Long-term results in 117 patients. Radiology 221, 159-166 (2001).
49. Baducci L, Stanta G. Cancer in the frail patient: a coming epidemic. Hematol. Oncol. Clin. N. Am. 14, 235-250 (2000).
50. Chen H, Cantor A, Meyer J et al. Can older cancer tolerate chemotherapy? A prospective pilot study. Cancer 97, 1107-1114 (2003).
51. Monfardini S, Sorio R, Boes GH et al. Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new drug development studies. Cancer 76, 333-338 (1995).
52. Stein BN, Petrelli NJ, Douglass HO et al. Age and sex are independent predictors of 5-FU toxicity. Analysis of large scale Phase III trial. Cancer 75, 11-17 (1995).
53. Chiara S, Nobile MT, Vicenti M et al. Advanced colorectal cancer in the ederly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother. Pharmacol. 42, 336-340 (1998).
54. Popescu RA, Norman A, Ross PJ et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J. Clin. Oncol. 17, 2412-2418 (1999).
55. Folprecht G, Cunningham D, Ross P et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann. Oncol. 15, 1330-1338 (2004).
56. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J. Clin. Oncol. 19, 4097-4106 (2001).
57. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol. 19, 2282-2292 (2001).
58. Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20, 3617-3627 (2002).
59. Douillard JY, Hoff PM, Skillings JR et al. Multicenter Phase III study of uracil/tegafur and oral leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20, 3605-3616 (2002).
60. Liu G, Franssen E, Ficht I et al. Patients preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 15, 110-115 (1997).
61. Feliu J, Gonzalez Baron M, Espinosa E et al. Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Cancer 79, 1884-1889 (1997).
62. Feliu J, Mel JR, Camps C et al. Raltitrexet in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen. Eur. J. Cancer 38, 1204-1211 (2002).
63. Feliu J, Escudero P, Llosa F et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group Study. J. Clin. Oncol. 23, 3104-3111 (2005).
64. Beretta G, Bollina R, Labianca R et al. A controlled trial of supportive care (SC) versus supportive care plus 5-fluorouracil/folinic acid for advanced metastatic gastrointestinal carcinomas in elderly. Proceedings of the American Society of Clinical Oncology, TX, USA, 13, 221 (1994).
65. Saltz LB, Cox N, Blanke LS et al. Irinotecan plus fluorouracil and leucovorin for metastatic 5FU colorectal cancer. N. Engl. J. Med. 343, 905-914 (2000).
66. Kohne CH, van Cutsem E, Wils J et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J. Clin. Oncol. 23, 4856-4865 (2005).
67. Bollina R, Beretta G, Toniolo D et al. Capiri: a good combination regimen in first line elderly CRC patients. Proceedings of the American Society of Clinical Oncology, IL, USA, 31 May-3 June, 332s, (2003).
68. Sastre J, Marcuello E, Massutti B et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group or the Treatment of Digestive Tumors Study. J. Clin. Oncol. 23, 3545-3551 (2005).
69. Buzzi F, Natale D, Farris A et al. Capecitabine (XEL) plus oxaliplatin (OX) tailored regimen for the first-line treatment of elderly patients (pts) with metastatic colorectal cancer (MCC). Final results of the Southern Italy Cooperative Oncology Group (SIGOG) trial 0108. Proceedings of the American Society of Clinical Oncology, FL, USA, 13-17 May, 266s (2005).
70. Salud A, Escudero P, Feliu J et al. XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/ metastatic colorectal cancer (MCRC). Proceedings of the American Society of Clinical Oncology, FL, USA, 13-17 May, 276s (2005).
71. Hurwith H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
72. Cunningham D, Humblet Y, Siena S et al. A randomised comparison of cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
73. Malik I, Hecht R, Patnaik A et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Proceedings of the American Society of Clinical Oncology, FL, USA, 13-17 May, 251 (2005).